Abstract：【Objective】To explore the effect of Aidi injection-assisted three-dimensional conformal radiotherapy (3D-CRT) in the treatment of patients with advanced esophageal cancer. 【Methods】A total of 96 patients with advanced esophageal cancer in our hospital from May 2017 to August 2021 were selected and divided into two groups according to the random number table method, with 48 cases in each group. The control group was treated with 3D-CRT, and the observation group was treated with Aidi injection in addition to 3D-CRT. The clinical effects, factors in peripheral blood mononuclear cells (PBMC) such as Th1 type transcription factor T-bet mRNA, Th2 type cytokine transcription factor GATA-3 mRNA and T-bet/GATA-3 before and after treatment, angiogenesis indexes [tumor vascular microdensity (MVD), serum vascular endothelial cell growth factor (VEGF), and angiopoietin 2 (Ang-2)] levels, quality of life (WHOQOL-BREF) score and the occurrence of acute radiation injury were compared between the two groups. 【Results】The total clinical effective rate of 70.83% (34/48) in the observation group, which was not statistically significant higher than that in the control group 60.42% (29/48) (P>0.05). After 3 weeks and 6 weeks of treatment, T-bet mRNA and T-bet/GATA-3 in PBMCs of the two groups were lower than before treatment, and GATA-3 mRNA was higher than before treatment. Compared with the control group, the difference was statistically significant (P<0.05). The levels of MVD, serum VEGF and Ang-2 in the observation group were lower than those in the control group after 3 and 6 weeks of treatment (P<0.05). The scores of physiological status, psychological status, social relationship, and physical environment in the WHOQOL-BREF scale in the observation group were higher than those in the control group after 6 weeks of treatment (P<0.05). 【Conclusion】The combination of Aidi injection and 3D-CRT in the treatment of advanced esophageal cancer has a good clinical effect and can reduce acute radiation injury. It can effectively improve cellular immune function in patients, and inhibit angiogenesis, which is of positive significance for improving the quality of life of patients.
[1] HUANG F L,YU S J. Esophageal cancer:Risk factors,genetic association and treatment[J].Asian J Surg,2018,41(3):210-215.
[2] 张岳琦,陈建平,孙静.内镜下判断食管早期鳞癌浸润深度的研究进展[J].临床内科杂志,2017,34(4):287-288.
[3] XIAO Z,LIANG R,WANG C Q,et al.Can Aidi injection alleviate the toxicity and improve the clinical efficacy of radiotherapy in lung cancer? A meta-analysis of 16 randomized controlled trials following the PRISMA guidelines[J].Medicine (Baltimore),2016,95(35):e4517.
[4] 郭鸿超.艾迪注射液配合化疗方案治疗食管癌术后的疗效分析[J].实用中西医结合临床,2017,17(11):39-41.
[5] KITAGAWA Y,UNO T,OYAMA T,et al.Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society:part 1[J].Esophagus,2019,16(1):1-24.
[6] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[7] ARNOLD M,LAVERSANNE M,BROWN L M,et al. Predicting the future burden of esophageal cancer by histological subtype:international trends in incidence up to 2030[J].Am J Gastroenterol,2017,112(8):1247-1255.
[8] 谢克北.三维适形放疗联合多西他赛治疗中晚期食管癌的疗效与安全性分析[J].现代肿瘤医学,2018,26(22):50-53.
[9] 冯晓飞.补益制癌饮对中晚期食管癌化疗患者生存质量与免疫功能的影响[J].中华中医药学刊,2019,37(4):1006-1008.
[10] 钟媛,张明,兰海涛.艾迪注射液联合TP治疗老年中晚期非小细胞肺癌观察[J].现代临床医学,2017,43(2):120-121.
[11] SHI Q,DIAO Y,JIN F,et al.Antimetastatic effects of Aidi on human esophageal squamous cell carcinoma by inhibiting epithelialmesenchymal transition and angiogenesis[J].Mol Med Rep,2018,18(1):131-138.
[12] 梁汉霖,彭杰文,魏莹.艾迪注射液联合顺铂、5-氟尿嘧啶治疗胃癌的临床疗效[J].深圳中西医结合杂志,2017,27(14):96-97.
[13] 李丹丹.ORAOV1、VEGF和MVD在食管鳞状细胞癌中的相关性研究[D].石河子:石河子大学,2017.
[14] LI N,LU Y,LI D,et al.All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma[J].PLoS One,2017,12(4):e0174555.
[15] 修艳丽,王璐,王晴,等.艾迪注射液对中晚期食管癌术后放化疗的疗效分析[J].中医临床研究,2018,10(31):87-88.
2022, Vol. 39 
